Genetic study of the CD36 gene in a French diabetic population

Diabetes and Metabolism

Volumn 30, Issue 5, 2004, Pages 459-463

  Lepretre F ^a   Linton, K J ^b   Lacquemant, C ^a   Vatin, V ^a   Samson, C ^a   Dina, C ^a   Chikri, M ^a,c   Ali, S ^b   Scherer, P ^d   Seron K ^a   Vasseur, F ^a   Aitman, T ^b   Froguel, P ^a,b,e  

^a INSTITUT PASTEUR DE LILLE   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Faculty of Medicine and Pharmacy   (Morocco)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adiponectin; CD36; Genetics; Insulin resistance; Type 2 Diabetes

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; CD36 ANTIGEN; INSULIN;

ALLELE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; FAMILY; FRANCE; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN SENSITIVITY; INTRON; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PROMOTER REGION;

EID: 10644230208     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70143-X     Document Type: Article

References (19)

1. Ohgami N, Nagai R, Ikemoto M, et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci, 2001, 947, 350-5.
2. Aitman TJ, Gotoda T, Evans AL, et al. Quantitative trait loci for cellular defects in glucose and fatty acid metabuolism in hypertensive rats. Nat Genet, 1997, 2, 197-201.
3. Aitman TJ, Glazier AM, Wallace CA, et al. Identification of CD36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet, 1999, 1, 76-83.
4. Ibrahimi A, Bonen A, Blinn WD, et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem, 1999, 38, 26761-6.
5. Coburn CT, Knapp FF Jr, Febbraio M, Beets AL, Silverstein RL, Abumrad NA. Defective uptake and utilization of long chain fatty-acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem, 2000, 42, 32523-9.
6. Pravenec M, Landa V, Zidek V, et al. Transgenic rescue of defective CD36 ameliorates insulin-resistance in spontaneously hypertensive rats. Nat Genet, 2001, 2, 156-8.
7. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, Matsuzawa Y. CD36 deficiency associated with insulin-resistance. Lancet, 2001, 9257, 686-7.
8. Vionnet N, Hani El-H, Dupont S, et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet, 2000, 6, 1470-80.
9. Vionnet N, Hani EH, Lesage S, et al. Genetics of NIDDM in France: studies with 19 candidate genes in affected sib pairs. Diabetes, 1997, 6, 1062-8.
10. Xie X and Ott J. Testing linkage disequilibrium between a disease gene and marker loci. Am J Hum Genet, 1993, 53, 1107.
11. Leprêtre F, Vasseur F, Vaxillaire M, et al. A CD36 nonsense mutation associated with insulin resistance and familial Type 2 diabetes. Human Mutation, 2004, 24, Issue 1.
12. Berglund L, Petersen TE, Rasmussen JT. Structural characterization of bovine CD36 from the milk fat globule membrane. Biochim et Biophys Acta, 1996, 1309, 63-8
13. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001, 86, 1930-5.
14. Vasseur F, Helbecque N, Dina C, et al. Single Nucleotide Polymorphism haplotypes in the both proximal promoter and exon 3 of APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for Type 2 Diabetes in French Caucasians. Hum Mol Gen, 2002, 11, 2607-14.
15. Yamauchi T, Hara K, Kubota N, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord, 2003, 4, 243-54.
16. Crawford DC, Carlson CS, Rieder MJ, et al. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet, 2004, 4, 610-22.
17. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001, 5, 1126-33.
18. Leprêtre F, Cheyssac C, Amouyel P, Froguel P, Helbecque N. A promoter polymorphism in CD36 is associated with an atherogenic lipid profile in a French general population. Atherosclerosis, 2004, 2, 373-5.
19. Leprêtre F, Vasseur F, Vaxillaire M, et al. A CD36 nonsense mutation associated with insulin resistance and familial Type 2 diabetes. Human Mutation, 2004, 24, Issue 1, 104.